Companies › Neurona Therapeutics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Neurology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NRTX-1001 GABA-secreting GABAergic interneurons derived from human embryonic stem cells | GABA | Phase 3 | Mesial Temporal Lobe Epilepsy; Epilepsy, Temporal Lobe | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06422923 | NRTX-1001 | Phase 1 | Epilepsy, Temporal Lobe | Neurology | Jun 2027 |
| NCT05135091 | NRTX-1001 | Phase 3 | Mesial Temporal Lobe Epilepsy | Neurology | Feb 2029 |
Sandoz Merz Pharmaceuticals Lupin Cytopeutics Sdn. Bhd. NKGen Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.